Partner
Press release
Gide, counsel to Remiges Ventures on its investment in Phost’in Therapeutics
Gide has advised investment fund Remiges Ventures on its investment in biopharmaceutical company Phost’in Therapeutics, which specialises in the discovery and development of N-glycosylation inhibitors for cancer treatment.
This investment was part of a Series A funding round of EUR 10.3 million, alongside Japanese fund ANRI and Irdi Soridec Gestion.
The transaction was completed on 9 April 2020.
Gide’s team advising Remiges Ventures comprised counsel Louis Oudot de Dainville and associate Marc Fournier on Corporate / M&A matters.